Endoplasmin-peptide complex (gp96-peptide complex) (gp96-peptide complex)

The gp96-peptide complex is a molecular assembly comprising the endoplasmic reticulum-resident chaperone gp96 (also known as endoplasmin or HSP90B1) and a variety of intracellularly derived peptides (UniProt P14625). These peptides are held within the chaperone's specialized cavity and represent a 'fingerprint' of the cell's protein expression, including mutated neoantigens in the case of cancer cells (Srivastava, 2002). The complex functions as a potent immunomodulator by interacting with the CD91 (LRP1) receptor on professional antigen-presenting cells, such as dendritic cells (Binder et al., 2000). Upon binding, the complex is internalized, and the chaperoned peptides are channeled into the MHC class I and II pathways for cross-presentation to T cells (Srivastava, 2002). This process bridges innate and adaptive immunity, facilitating the generation of a specific cytotoxic T-lymphocyte response against tumor or infected cells (Testori et al., 2008). Therapeutically, autologous gp96-peptide complexes have been developed as personalized cancer vaccines, most notably vitespen (Oncophage), to treat malignancies like melanoma and renal cell carcinoma (Wood et al., 2008). The efficacy of these vaccines depends on the diversity and relevance of the peptides captured within the gp96 cavity relative to the patient's tumor profile (Srivastava, 2002). Beyond cancer, gp96-peptide complexes are also being investigated for their role in infectious diseases and as adjuvants to enhance vaccine potency (Srivastava, 2002).

Other names

GRP94-peptide complexHSP90B1-peptide complexTumor-derived gp96HSPPC-96Vitespen

The gp96-peptide complex interacts with the CD91 (LRP1) receptor on professional antigen-presenting cells, leading to the internalization of the complex and subsequent cross-presentation of the chaperoned peptides on MHC class I and II molecules to activate specific T-cell responses (Binder et al., 2000; Srivastava, 2002).